OLX 103

Drug Profile

OLX 103

Alternative Names: AR 103; L 691912; TGF-alpha-PE40; TP40; Transforming growth factor-alpha-PE40

Latest Information Update: 07 May 1998

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Merck & Co
  • Class Antineoplastics
  • Mechanism of Action Epidermal growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 07 May 1998 Discontinued-II for Cancer in USA (Intravesicular)
  • 07 Mar 1996 A study has been added to the pharmacodynamics section
  • 15 May 1995 Phase-II clinical trials for Cancer in USA (Intravesicular)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top